AJANTPHARM · Healthcare
Ajanta Pharmaceuticals Ltd. reported revenue of ₹1,028 cr for July to September 2023, — on the year and +0.7% on the quarter.
Operating profit (EBITDA) was ₹291 cr, a margin of 28.3%, — on the year and +176 bps on the quarter.
Net profit was ₹195 cr, — on the year and −6.3% on the quarter, with earnings per share of ₹15.24.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow filed with this quarter, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Could not run on this quarter: Headline vs core profit, Exceptional items that recur, Operating margin on the year, Depreciation falling, Finance cost rising, Swing to loss or profit, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
This quarter's filing carries a balance sheet and a cash flow statement. The cash, receivables and borrowing checks run once the filing read is in.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,028 cr | ₹1,105 cr | ₹1,054 cr | ₹1,145 cr | ₹1,187 cr | ₹1,146 cr | ₹1,170 cr | ₹1,303 cr | ₹1,354 cr | ₹1,375 cr | ₹1,422 cr | ₹1,626 cr |
| YoY | — | — | — | +12% | +15% | +4% | +11% | +14% | +14% | +20% | +22% | +25% |
| EBITDA margin | 28.3% | 28.4% | 26.4% | 28.8% | 26.2% | 28.0% | 25.4% | 26.9% | 24.2% | 27.8% | 23.4% | 26.1% |
| Other income, % of PBT | 8% | 5% | 13% | 8% | 7% | 10% | 7% | 8% | 17% | 7% | 18% | 16% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 29% | 28% | 27% | 24% | 25% | 24% | 16% | 23% | 24% | 24% | 23% | 25% |
| Net profit | ₹195 cr | ₹210 cr | ₹203 cr | ₹246 cr | ₹216 cr | ₹233 cr | ₹225 cr | ₹255 cr | ₹260 cr | ₹274 cr | ₹267 cr | ₹334 cr |
| YoY | — | — | — | +18% | +11% | +11% | +11% | +4% | +20% | +18% | +19% | +31% |
| Core profit YoY | — | — | — | +25% | +6% | 0% | +4% | +3% | +4% | +21% | +14% | +23% |
| EPS | ₹15.24 | ₹16.39 | ₹15.82 | ₹19.68 | ₹17.33 | ₹18.64 | ₹18.03 | ₹20.44 | ₹20.83 | ₹21.91 | ₹21.35 | ₹26.75 |
| Flags | · | · | · | ✓ | ✓ | ✓ | ✓ | ✓ | 1 | ✓ | ✓ | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Ajanta Pharmaceuticals Ltd. reported revenue of ₹1,028 cr (— on the year) and net profit of ₹195 cr (— on the year) for July to September 2023.
None of the 2 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.